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Abstract
Atorvastatin has been shown to reduce resistin expression in macrophages after pro-inflammatory
stimulation. However, the mechanism of reducing resistin expression by atorvastatin is not known.
Therefore, we sought to investigate the molecular mechanisms of atorvastatin for reducing resistin
expression after proinflammatory cytokine, tumor necrosis factor- (TNF-) stimulation in
cultured macrophages. Cultured macrophages were obtained from human peripheral blood
mononuclear cells. TNF- stimulation increased resistin protein and mRNA expression and
atorvastatin inhibited the induction of resistin by TNF-. Addition of mevalonate induced resistin
protein expression similar to TNF- stimulation. However, atorvastatin did not have effect on
resistin protein expression induced by mevalonate. SP600125 and JNK small interfering RNA
(siRNA) completely attenuated the resistin protein expression induced by TNF- and mevalonate.
TNF- induced phosphorylation of Rac, while atorvastatin and Rac-1 inhibitor inhibited the
phosphorylation of Rac induced by TNF-. The gel shift and promoter activity assay showed that
TNF- increased AP-1-binding activity and resistin promoter activity, while SP600125 and
atorvastatin inhibited the AP-1-binding activity and resistin promoter activity induced by TNF-.
Recombinant resistin and TNF- significantly reduced glucose uptake in cultured macrophages,
while atorvastatin reversed the reduced glucose uptake by TNF-. In conclusion, JNK and Rac
pathway mediates the inhibitory effect of atorvastatin on resistin expression induced by TNF-.
Background
Resistin is an adipocyte-secreted molecule induced during
adipocyte differentiation. Recombinant resistin up-regu-
lates cytokines and adhesion molecule expression on
human endothelial cells [1,2], suggesting a potential role
in atherosclerosis. Resistin has been shown to have potent
proinflammatory properties [3]. Resistin promotes
endothelial cell activation and causes endothelial dys-
function of porcine coronary arteries [4]. Recently, resistin
was found to have a potential role in atherosclerosis
because resistin increases MCP-1 and sVCAM-1 expres-
sion in vascular endothelial cells and resistin promotes
vascular smooth muscle cell proliferation [5,6]. More
recently, resistin was found to be secreted from macro-
phages in atheromas and promotes atherosclerosis [7].
Plasma resistin levels are correlated with markers of
inflammation and are predictive of coronary atherosclero-
sis in humans, independent of plasma C – reactive pro-
tein. Resistin may represent a novel link between
metabolic signals, inflammation, and atherosclerosis [8].
Published: 27 May 2009
Journal of Biomedical Science 2009, 16:50 doi:10.1186/1423-0127-16-50
Received: 21 December 2008
Accepted: 27 May 2009
This article is available from: http://www.jbiomedsci.com/content/16/1/50
© 2009 Shyu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The cost of publication in Journal of Biomedical Science
is bourne by the National Science Council, Taiwan.Journal of Biomedical Science 2009, 16:50 http://www.jbiomedsci.com/content/16/1/50
Page 2 of 12
(page number not for citation purposes)
The 3-hydroxy 3-methyl glutaryl-CoA reductase (HMG-
CoA reductase) inhibitors or statins have been proved to
reduce inflammation and exert beneficial effects in the
prevention of atherosclerosis progression [9]. The pleio-
tropic effect of statins, independent of their lipid-lowering
effects have been described to improve endothelial func-
tion, stabilize atheroslerotic plaque, inhibit vascular
smooth muscle cell proliferation as well as platelet aggre-
gation, and reduce vascular inflammation [9]. Ichida et al
reported that atorvastatin decreases resistin expression in
adipocytes and monocytes/macrophages [10]. Atorvasta-
tin decreased resistin mRNA expression in a dose- and
time-dependent manner. However, the mechanism of
reducing resistin expression by atorvastatin is not known.
Therefore, we sought to investigate the molecular mecha-
nisms of atorvastatin for reducing resistin expression after
proinflammatory cytokine, TNF- stimulation in macro-
phages.
Materials and methods
Drugs
Atorvastatin, a calcium salt of a pentasubstituted pryole,
was supplied by Pfizer. A 10-mmole/l stock solution was
made in 100% DMSO. Recombinant TNF- protein and
mevalonate were purchased from Sigma; Polyclonal Rac,
and polyclonal phospho-Rac1 (Ser71) antibodies from
Cell Signaling; Resistin antibody from R&D Systems; Rac
1 inhibitor, PD 98059, SB 203580, and anisomycin from
CALBIOCHEM; Resistin siRNA from Invitrogen.
Cell culture
Human peripheral mononuclear cells (PBMCs) were iso-
lated from heparinized whole blood obtained from nor-
mal healthy volunteers by Ficoll-Hypaque gradient
centrifugation. The cells were washed three times with
sterile PBS and resuspended in RPMI 1640 supplemented
with 10% fetal calf serum, 2 mmol/l L-glutamate and 1%
penicillin/streptomycin. Monocytes were purified from
PBMCs by positive selection using anti-CD14 magnetic
beads according to the manufacturer's instructions. The
cells were cultured for 4 days in RPMI 1640 supplemented
with 10% fetal calf serum, 2 mmol/l L-glutamate and 1%
penicillin/streptomycin. For experimental use, purified
monocytes/macrophages were changed to serum-free
RPMI-1640 supplemented with 2 mmol/l L-glutamate
and 1% penicillin/streptomycin for 6 h, then treated with
either 1 or 10 mol/l of atorvastatin for 24 and 48 h.
Western blot analysis
Cells were homogenized in modified RIPA buffer. Equal
amounts of protein (15 g) were loaded into a 12.5%
SDS-polyacrylamide minigel, followed by electrophore-
sis. Protein samples were mixed with sample buffer,
boiled for 10 min, separated by SDS-PAGE under denatur-
ing conditions, and electroblotted to nitrocellulose mem-
branes. The blots were incubated overnight in Tris-
buffered saline (TBS) containing 5% milk to block non-
specific binding of the antibody. Proteins of interest were
revealed with specific antibodies as indicated (1:1000
dilution) for 1 hour at room temperature followed by
incubation with a 1:5000 dilution of horseradish peroxi-
dase-conjugated polyclonal anti-rabbit antibody for 1 h at
room temperature. Signals were visualized by chemilu-
minenescent detection. Equal protein loading of the sam-
ples was further verified by staining monoclonal antibody
GAPDH. All Western blots were quantified using densit-
ometry.
RNA isolation and reverse transcription
Total RNA was isolated from cultured macrophages using
the single-step acid guanidinium thiocyanate/phenol/
chloroform extraction method. Total RNA (1g) was incu-
bated with 200U of Moloney-Murine Leukemia Virus
reverse transcriptase in a buffer containing a final concen-
tration of 50 mmol/L TrisCl (pH 8.3), 75 mmol/L KCl, 3
mmol/MgCl2, 20 U of RNase inhibitor, 1 mol/L polydT
oligomer, and 0.5 mmol/L of each dNTP in a final volume
of 20 L. The reaction mixture was incubated at 42°C for
1 h and then at 94°C for 5 min to inactivate the enzyme.
A total of 80 L of diethyl pyrocarbonate treated water was
added to the reaction mixture before storage at -70°C.
Real-time PCR
A Lightcycler (Roche Diagnostics, Mannheim, Germany)
was used for real-time PCR. cDNA was diluted with nucle-
ase-free water. 2 L of the solution was used for the Light-
cycler SYBR-Green mastermix (Roche Diagnostics): 0.5
mol/L primer, 5 mmol/L magnesium chloride, and 2 L
Master SYBR-Green in nuclease-free water in a final vol-
ume of 20 L. The primer used for mouse resistin was: for-
ward, 5'-d(GTACCCACGGGATGAAGAACC)-3'; reverse,
5'-d(GCAGACCCACAGGAGCAG)-3'. The primer used for
human resistin was: forward, 5'-d(TAAGCAGCATT-
GGCCTGG)-3'; reverse, 5'-d(CTGTGGCTCGT-
GGGATGT)-3'. GAPDH: forward, 5'-
d(CATCACCATCTTCCAGGAGC)-3'; reverse, 5'-d(GGAT-
GATGTTCTGGGCTGCC)-3'. The initial denaturation
phase was 10 min at 95°C followed by an amplification
phase as detailed below: denaturation at 95°C for 10 sec;
annealing at 55°C for 5 sec; elongation at 72°C for 15 sec
and for 30 cycles. Amplification, fluorescence detection,
and post-processing calculation were performed using the
Lightcycler apparatus. Individual PCR products were ana-
lyzed for DNA sequence to confirm the purity of the prod-
uct.
Electrophoretic mobility shift assay (EMSA)
Nuclear protein concentrations from macrophages were
determined by Biorad protein assay. Consensus and con-
trol oligonucleotides (Santa Cruz Biotechnology Inc.)Journal of Biomedical Science 2009, 16:50 http://www.jbiomedsci.com/content/16/1/50
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were labeled by polynucleotides kinase incorporation of
[32P]-ATP. Oligonucleotides sequences included the acti-
vating protein 1 (AP-1) consensus 5'-CGCTTGATGACT-
CAGCCGGAA-3'. The AP-1 mutant oligonucleotides
sequences were 5'-CGCTTGATGACTTGGCCGGAA-3'.
After the oligonucleotide was radiolabeled, the nuclear
extracts (4 g of protein in 2 l of nuclear extract) were
mixed with 20 pmol of the appropriate [32P]-ATP-labeled
consensus or mutant oligonucleotide in a total volume of
20 l for 30 min at room temperature. The samples were
then resolved on a 4% polyacrylamide gel. Gels were dried
and imaged by autoradiography. Controls were per-
formed in each case with mutant oligonucleotides or cold
oligonucleotides to compete with labeled sequences.
Promoter activity assay
A-741 to +22 bp rat resistin promoter construct was gen-
erated as follows. Rat genomic DNA was amplified with
forward primer (ACGCGTCTCAGCGGTAGAGCTCTTG)
and reverse primer (AGATCTGGAGAAATGAAAGGTTCT-
TCATC). The amplified product was digested with MluI
and BglII restriction enzymes and ligated into pGL3-basic
luciferase plasmid vector (Promega Corp. Madison, Wis-
consin, USA) digested with the same enzymes. The resis-
tin promoter contains AP-1 conserved sites (CT) at -51 to
-52 bp. For the mutant, the AP-1 binding sites were
mutated using the mutagenesis kit (Stratagene, La Jolla,
California, USA). Site-specific mutations were confirmed
by DNA sequencing. Plasmids were transfected into mac-
rophages using a low pressure-accelerated gene gun (Bio-
ware Technologies, Taipei, Taiwan) essentially following
the protocol from the manufacturer. Test plasmid at 2 g
and control plasmid (pGL4-Renilla luciferases) 0.02 g
were cotransfected with gene gun in each well, and then
replaced by normal culture medium. Following 4 hours of
TNF- stimulation, cell extracts were prepared using Dual-
Luciferase Reporter Assay System (Promega) and meas-
ured for dual luciferase activity by luminometer (Turner
Designs).
Measurement of resistin concentration
Conditioned media from cultured macrophages under
TNF- stimulation and those from control cells were col-
lected for resistin measurement. The level of resistin was
measured by a quantitative sandwich enzyme immu-
noassay technique (R&D Systems). The lower limit of
detection of resistin was 5 pg/mL. Both the intra-observer
and inter-observer coefficient of variance were < 10%.
Glucose uptake in macrophages
Macrophages were seeded on ViewPlate for 60 min (Pack-
ard Instrument Co., Meriden, Connecticut, USA) at a cell
density of 5 × 103 cells/well in serum free medium with
transferring 5 g/mL, insulin 5. g/mL for overnight.
Recombinant TNF- protein or conditioned medium
were added to the medium. Glucose uptake was per-
formed by adding 0.1 mmol/L 2-deoxy-D-glucose and
3,33 nCi/mL 2- [1,2-3H]-deoxy-D-glucose for various
periods of time. Cells were washed with PBS twice. Non-
specific uptake was performed in the presence of 10 M
cytochalasin B and subtracted from all of the measured
value. MicroScint-20 50 l was added and the plate was
read with TopCount (Packard Instrument Co.). The radi-
oactivity was counted and normalized to protein amount
measured with a protein assay kit.
Statistical analysis
The data were expressed as mean+S.E.M. Statistical signif-
icance was performed with analysis of variance followed
by Dunnett's test for experiments consisting of more than
two groups and with Student's t test for stretch at 10% and
20%. A value of P < 0.05 was considered to denote statis-
tical significance.
Results
TNF- increases resistin expression in human 
macrophages
Western blot was used first to investigate the effect of TNF-
 on resistin expression in human macrophages. As
shown in Fig. 1, resistin protein expression was signifi-
cantly induced at 4 h after TNF- (1 ng/mL) stimulation,
maximally induced at 18 h, and remained elevated for 48
h. The expression of resistin messenger RNA was signifi-
cantly induced by TNF- from 4 to 18 h of stimulation
(Fig. 1C).
Atorvastatin inhibited the effect of TNF- on resistin 
expression
To test whether atorvastatin can inhibit the effect of TNF-
 on resistin expression in human macrophages, different
doses of atorvastatin was added before TNF- stimula-
tion. As shown in Fig. 2, atorvastatin inhibited the resistin
protein expression induced by TNF- in a dose-dependent
manner. Addition of mevalonate at 200 M for 18 h
induced resistin protein expression similar to TNF- stim-
ulation (Fig. 3A and 3B). However, atorvastatin did not
have effect on resistin protein expression induced by
mevalonate. Atorvastatin alone had neutral effect on resis-
tin expression similar to control cells. Exogenous meval-
onate did not reverse the resistin protein expression
induced by TNF- stimulation. This finding implicated
that mevalonate has proinflammatory effect on resistin
expression in human macrophages and atorvastatin
inhibited the TNF--induced resistin expression not via
HMG-CoA reductase pathway. SP600125, a potent inhib-
itor of JNK, completely attenuated the resistin protein
expression induced by TNF- and mevalonate (Fig. 4A
and 4B). PD98059, a potent inhibitor of p42/p44 MAP
kinase, and SB203580, a potent inhibitor of p38 MAP
kinase, partially attenuated the resistin protein expressionJournal of Biomedical Science 2009, 16:50 http://www.jbiomedsci.com/content/16/1/50
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Effect of pro-inflammatory cytokine, tumor necrosis factor- (TNF-) on resistin expression in cultured macrophages Figure 1
Effect of pro-inflammatory cytokine, tumor necrosis factor- (TNF-) on resistin expression in cultured mac-
rophages. (A) Representative Western blots for resistin in macrophages treated with TNF- for different periods of time. (B 
and D) (B) Quantitative analysis of resistin protein levels. The values from treated macrophages have been normalized to val-
ues in control cells. (n = 4 per group). *P < 0.01 vs. control. (C) Quantitative analysis of resistin mRNA levels. The mRNA level 
was measured by real-time PCR. The values from treated macrophages have been normalized to matched actin measurement 
and then expressed as a ratio of normalized values to mRNA in control cells (n = 3 per group). *P < 0.01 vs. control.
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induced by TNF- and mevalonate. NAC, an antioxidant
scavenger, did not affect the resistin protein expression
induced by TNF- and mevalonate. TNF- stimulation
increased phosphorylation of JNK (Additional file 1),
while TNF- stimulation did not increase phosphoryla-
tion of p38 kinase and increased phosphorylation of ERK
only after stimulation for 2 h. SP 60025 and Rac1 inhibi-
tor significantly attenuated the phosphorylation of JNK
induced by TNF- stimulation. Atorvastatin also signifi-
cantly reduced the phosphorylated JNK induced by TNF-
 stimulation. These findings indicate that JNK pathway is
the main signal pathway mediating the induction of resis-
tin protein expression by TNF-. Our data also demon-
strated that Rac was also involved in TNF- induced JNK
activation.
Rac pathway mediates the inhibitory effect of atorvastatin 
on resistin expression induced by TNF-
To investigate the atorvastatin inhibitory mechanism on
induction of resistin by TNF-, rac pathway was studied.
As shown in Fig. 5, TNF- induced phosphorylation of
Rac in a dose-dependent manner. TNF- did not haveJournal of Biomedical Science 2009, 16:50 http://www.jbiomedsci.com/content/16/1/50
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Atorvastatin inhibits the resistin protein expression induced by TNF- in a dose-dependent manner Figure 2
Atorvastatin inhibits the resistin protein expression induced by TNF- in a dose-dependent manner. A, Repre-
sentative Western blots for resistin in macrophages treated with TNF- with or without atorvastatin. B, Quantitative analysis 
of resistin protein levels. The values from treated macrophages have been normalized to values in control cells. (n = 4 per 
group). *P < 0.05 vs. TNF-. **P < 0.001 vs. TNF-.
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Atorvastatin inhibits the TNF--induced resistin expression not via HMG-CoA reductase pathway Figure 3
Atorvastatin inhibits the TNF--induced resistin expression not via HMG-CoA reductase pathway. A. Repre-
sentative Western blots for resistin in macrophages treated with TNF-, mevalonate with or without atorvastatin. B, Quanti-
tative analysis of resistin protein levels. The values from treated macrophages have been normalized to values in control cells. 
(n = 4 per group). *P < 0.001 vs. TNF-.
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JNK pathway is the main signal pathway mediating the induction of resistin protein expression by TNF- and mevalonate Figure 4
JNK pathway is the main signal pathway mediating the induction of resistin protein expression by TNF- and 
mevalonate. A. Representative Western blots for resistin in macrophages treated with TNF- with or without different 
inhibitors. B, Quantitative analysis of resistin protein levels. The values from treated macrophages have been normalized to val-
ues in control cells. (n = 4 per group).
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TNF- induces phosphorylation of rac protein expression in cultured macrophages Figure 5
TNF- induces phosphorylation of rac protein expression in cultured macrophages. A. Representative Western 
blots for phospho-rac and total rac in macrophages treated with TNF- with or without atorvastatin. B, Quantitative analysis 
of phospho-rac protein levels. The values from treated macrophages have been normalized to values in control cells. (n = 4 per 
group). *P < 0.001 vs. control.
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effect on total Rac. Addition of atorvastatin inhibited the
phosphorylation of Rac induced by TNF-. Rac-1 inhibi-
tor almost completely attenuated the effect of TNF- on
resistin induction (Fig. 6). Anisomycin, an agonist of Rac,
significantly increased the resistin protein expression sim-
ilar to TNF-. Rac1 inhibitor attenuated the induction of
resistin protein expression by TNF-, while rac1 inhibitor
did not alter the resistin protein expression induced by
anisomycin. As shown in Additional file 2, addition of
mevalonate did not induce phosphorylation of Rac and
total rac protein expression.
TNF- increases AP-1-binding activity and resistin 
promoter activity
The EMSA assay showed that TNF- increased AP-1 DNA-
protein binding activity (Fig. 7). An excess of unlabeled
AP1 oligonucleotide competed with the probe for binding
AP1 protein, whereas an oligonucleotide containing a 2-
bp substitution in the AP1 binding site did not compete
for binding. Addition of SP600125 and atorvastatin 30
min before TNF- stimulation abolished the DNA-protein
binding activity induced by TNF-. DNA-binding com-
plexes induced by TNF- could be supershifted by a mon-
oclonal AP-1 antibody, indicating the presence of this
protein in these complexes.
To study whether the resistin expression induced by TNF-
 is regulated at the transcriptional level, we cloned the
promoter region of rat resistin (-741~+22), and con-
structed a luciferase reporter plasmid (pGL3-Luc). The
resistin promoter construct contains Stat-3, SRE, NF-B,
and AP1 binding sites. As shown in Fig. 7B and 7C, tran-
sient transfection experiment in macrophages using this
reporter gene revealed that TNF- stimulation for 4 h sig-
nificantly caused resistin promoter activation. This result
indicates that resistin expression is induced at transcrip-
Rac pathway mediates the inhibitory effect of atorvastatin on resistin expression induced by TNF- Figure 6
Rac pathway mediates the inhibitory effect of atorvastatin on resistin expression induced by TNF-. A. Repre-
sentative Western blots for resistin in macrophages treated with TNF- with or without atorvastatin and different inhibitors. 
B, Quantitative analysis of resistin protein levels. The values from treated macrophages have been normalized to values in con-
trol cells. (n = 3 per group). *P < 0.001 vs.*P < 0.01 vs. TNF-.
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tional level by TNF-. When the AP1 binding sites were
mutated, the increased promoter activity induced by TNF-
 was abolished. Moreover, addition of SP600125 and
atorvastatin caused an inhibition of transcription. These
results suggested that AP1 binding site in the resistin pro-
moter is essential for the transcriptional regulation by
TNF- and that TNF- regulates resistin promoter via JNK
pathways.
TNF- stimulates secretion of resistin from macrophages 
and reduces glucose uptake
As shown in Fig. 8A, TNF- significantly increased the
resistin secretion from cultured macrophages from 4 to 24
TNF- increases AP-1-binding activity and resistin promoter activity Figure 7
TNF- increases AP-1-binding activity and resistin promoter activity. A. Representative EMSA showing protein bind-
ing to the AP-1 oligonucleotide in nuclear extracts of macrophages after TNF- treatment in the presence or absence of ator-
vastatin or JNK inhibitor. Similar results were observed in another two independent experiments. A significant supershifted 
complex (super) after incubation with AP-1 antibody was observed. Cold oligo means unlabeled AP-1 oligonucleotides. B. Con-
structs of resistin promoter gene. Positive +1 demonstrates the initiation site for the resistin transcription. Mutant resistin pro-
moter indicates mutation of AP-1 binding sites in the resistin promoter as indicated. C. Quantitative analysis of resistin 
promoter activity. Cultured macrophages were transiently transfected with pResistin-Luc by gene gun. The luciferase activity in 
cell lysates was measured and was normalized with renilla activity (n = 3 per group). *P < 0.001 vs. control. +P < 0.01 vs. 4 h.
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h. The mean concentration of resistin rose from 98 ± 13
pg/mL before TNF- stimulation to 542 ± 64 pg/mL after
TNF- stimulation for 18 h (P < 0.01). Pretreatment with
atorvastatin or SP600125 significantly attenuated the
secretion of resistin induced by TNF-
Recombinant TNF- protein at 1 ng/mL significantly
reduced glucose uptake at various periods of incubation
as compared to control macrophages without treatment
(Additional file 3). As shown in Figure 8B, exogenous
addition of conditioned medium from TNF- stimulated
macrophages and resisitn also increased glucose uptake in
cultured macrophages. To eliminate the TNF- effect on
glucose uptake, anti-rat TNF- antibody (5 g/ml, pur-
chased form R&D Systems) was added to the medium 1
hour before 2- [1,2-3H]-deoxy-D-glucose was added. The
effect of cultured medium obtained from macrophages
after TNF- antibody treatment on reducing glucose
TNF- stimulates secretion of resistin from macrophages and reduces glucose uptake Figure 8
TNF- stimulates secretion of resistin from macrophages and reduces glucose uptake. (A) TNF- at 1 ng/mL sig-
nificantly increasesd release of resistin from cultured macropghes at different stimulation periods. SP600125 and atorvastatin 
attenuated the effect induced by TNF- (n = 3). *P < 0.01 vs. control. **P < 0.001 vs. control.+P < 0.001 vs. 18 hr. (B) Resistin 
and conditioned medium (CM) after TNF- treatment had similar effect on reducing glucose uptake. Glucose uptake was meas-
ured in macrophages treated for 90 min with 20 g/mL recombinant resisitn protein or conditioned medium from cultured 
macrophages after 1 ng/mL TNF- stimulation with or without TNF- antibody (TNF- Ab). *P < 0.05 vs. control. **P < 0.01 
vs. control. Data are from 3 independent experiments.
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uptake was similar to that of resistin. Addition of resistin
siRNA or atorvastatin before recombinant resistin treat-
ment reversed the glucose uptake to baseline levels (Addi-
tional file 3). This data indicates that resistin secreted
from macrophage after TNF- stimulation is functional.
Discussion
Atherosclerosis has been considered an inflammatory dis-
ease. Inflammatory mediators such as TNF-, interleukin-
1 and C-reactiv protein paly an important role in atheo-
genesis. Resistin could stimulate expression of TNF-,
interleukin-1, 6 and 12 in cultured macrophages [3,11].
We have previously demonstrated a remarkable induction
of resistin protein level even after stimulation with low
level of TNF- in vascular smooth muscle cells [12]. In
this study, we further demonstrated that resistin protein
and mRNA levels can be induced by TNF- in cultured
human macrophages. Macrophages and vascular smooth
muscle cells are important components in the atheroma.
These findings indicate that resistin is a promising target
for controlling atherosclerotic disease.
Biomarkers that integrate metabolic and inflammatory
signals are attractive candidates for defining risk of athero-
sclerotic cardiovascular disease [13]. Hyperresistinemia
impairs glucose tolerance and induces hepatic insulin
resistance in rodents [14], whereas mice deficient in resis-
tin are protected from obesity associated insulin resistance
[15]. In this study, we also demonstrated that recom-
binant resistin protein and TNF- reduced glucose uptake
in human macrophages and atorvastatin reversed the
abnormal glucose uptake induced by resistin and TNF-.
Resistin may represent a novel link between metabolic sig-
nals, inflammation, and atherosclerosis [16].
Norata et al. have reported that plasma resistin levels are
increased in the presence of metabolic syndrome and are
associated with increased cardiovascular risk [17]. Lubos
et al. have also reported that resistin levels are elevated in
patients with acute coronary syndrome and might play a
role as a diagnostic marker [18]. Recently, resistin was
found to induce lipolysis and re-esterification of triacylg-
lycerol stores and increase cholesteryl ester deposition in
human macrophages [19]. Therefore, resistin contributes
macrophage form cell formation. Statins have been
shown to reduce lipid lowering effects as well as pleio-
tropic properties. Although statin cannot alter resistin lev-
els in patients with type 2 diabetic and in healthy men
[20-22], statins have been shown to reduce resistin expres-
sion in human monocytes and adipocytes [10,23]. These
data implicate that statins may control inflammatory
responses by inhibiting resistin expression.
Indeed, our study demonstrated that TNF- induced resis-
tin protein and mRNA expression in human macrophages
and atorvastatin decreased TNF--induced resistin expres-
sion in a dose-dependent manner. The induction of resis-
tin protein by TNF- was largely mediated by JNK kinase
pathway because the specific and potent inhibitors of an
upstream JNK kinase, SP600125, inhibited the induction
of resistin protein. Atorvastatin also inhibited the phos-
phorylation of rac induced by TNF-. In this study, we
demonstrated that TNF- stimulation of AP-1-DNA bind-
ing activity required at least phosphorylation of the JNK
since JNK inhibitor abolished the AP-1 binding activity.
Atorvastatin also attenuated the AP-1 binding activity
induced by TNF-. The promoter activity of wild resistin
promoter after TNF- was significantly higher than that of
AP-1 mutant resistin promoter. This finding indicates that
TNF- regulates resistin in human macrophages at tran-
scriptional level and that AP-1 binding sites in the resistin
promoter is essential for the transcriptional regulation.
Taken together, our results indicate that TNF- may
increase the AP-1 transcriptional activity in macrophages.
Resistin induced by TNF- was largely though JNK, rac
and resistin promoter pathways and atorvastatin could
inhibit resistin expression through inhibition of rac phos-
phorylation, reduced AP-1 binding activity and resistin
promoter activity.
In our study, we demonstrated that inhibition of the TNF-
-induced resistin expression by atorvastatin was inde-
pendent of HMG-CoA reductase. Downregulation of
resistin expression induced by CRP by simvastatin was
independent of HMG-CoA reductase [23]. Rac pathway
mediates the signal trasndcution by isoprenoid intermedi-
ates, such as farnesylpyrophosphate and geranylgeranyl-
pyrophosphate. In this study, we did not test the effect of
isoprenoid intermediate on inhibition of TNF--induced
resistin expression by atorvastatin. We demonstrated that
TNF- and mevalonate induce resisitn at the similar level.
However, atorvastatin only blocks TNF- but not meval-
onate induced resistin. TNF- but not mevalonate induces
rac phosphorylation in cultured macrophages. JNK spe-
cific inhibitor S600125 blocked both TNF- and meval-
onate induced resistin expression. This data suggests that
mevalonate plays a proinflammatory role and atorvasta-
tin attenuates resistin expression induced by TNF- is
independent of HMG-CoA reductase but through inhibi-
tion of Rac and JNK pathway.
In conclusion, our study confirmed previous findings that
TNF- could induce resistin expression in human macro-
phages and atorvastatin could inhibit the resistin expres-
sion induced by TNF-. The inhibitory effect of
atorvastatin on TNF--induced resistin expression was
mediated by rac and resistin promoter. Our findings pro-
vide another evidence of pleiotropic effect of statin. Statin
therapy may become another therapeutic strategy for con-Journal of Biomedical Science 2009, 16:50 http://www.jbiomedsci.com/content/16/1/50
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trolling resistin-associated pathologic cardiovascular dis-
ease in humans.
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